Nuance Plans an Offering, Memsic Makes Disappointing Debut, Inverness Orders the Usual, & More

12/17/07

The Boston-area biz/tech news was piling up almost as fast as the snow last week, and there were a few deals we didn’t manage to plow through at the time. Here they are, along with a few of the ones we caught the first time around.

—Nuance Communications (NASDAQ: NUAN), which sells speech and imaging software, announced a 15 million-share secondary public offering of its stock, with 9.6 million shares being offered by the firm, 4.8 million coming from shareholder Warburg Pincus, and 600,000 shares offered by members of Nuance’s management. The stock fell on the news, closing Friday at $19.00 after having closed Tuesday (just before the announcement) at $21.11.

—For the umpteenth time this year, Waltham, MA-based Inverness Medical Innovations (AMEX: IMA) announced it’s making an acquisition. This time the diagnostics giant is picking up U.K. firm BBI Holdings for $170 million.

—North Reading, MA’s Teradyne (NYSE: TER), which produces System-On-a-Chip (SOC) test products, announced it would acquire Nextest Systems (NASDAQ: NEXT), a maker of flash memory test products, for some $325 million.

—RSS feed aggregator firm NewsGator Technologies of Denver closed a $12 million funding round led by Vista Ventures and joined by Mobius Venture and Masthead Venture Partners. The jury’s still out on whether it’s a tattoo-worthy deal.

—Quincy, MA-based Modiv Media, which provides software that delivers relevant ads and other product information to consumers on in-store systems and over cell phones, has raised $8 million in Series A funding, according to peHUB, which cites a regulatory filing. Backers reportedly include Ignition Partners, Oak Investment Partners, and SeaPoint Ventures. Modiv’s customers include Stop & Shop, Giant Eagle, and Subway.

—Andover, MA-based sensor-maker Memsic (NASDAQ: MEMS) had a disappointing stock market debut, gaining only 25 cents in its first day of trading after dropping the price from between $11 and $13 per share to $10 per share.

—Boston Scientific (NYSE: BSX) inked an agreement to sell the last two of five businesses it had identified as “non-strategic” in a previously announced restructuring plan. The deal, with private equity firm Avista Capital Partners, will bring the Natick-based firm $425 million in cash.

By posting a comment, you agree to our terms and conditions.